Abstract
Background: The prevalence of Type 2 Diabetes Mellitus (T2DM) is increasing worldwide; this is stimulating more research into the optimal management of this disease. Cardiovascular Disease (CVD) remains the commonest cause of death in individuals with T2DM. Besides hyperglycaemia, an explanation for the increased mortality in this population is the increased prevalence of comorbidities, such as hypertension and dyslipidaemia. Recent population-based studies described a prevalence of hypertension >80% in patients with T2DM. In the last decade new classes of antidiabetic medications have been developed that are effective not only for the management of hyperglycaemia and but also for tailoring treatment according to individual needs and characteristics. Regulatory authorities demand the new antidiabetic medications to be examined for Cardiovascular (CV) safety. Interestingly it has been shown, mainly through CV safety trials, that some new antidiabetic medications not only have glucose lowering effects, but also Blood Pressure (BP) lowering effects, contributing to CV risk reduction.
Conclusion: This review considers the effect of older and newer antidiabetic medications on BP in patients with T2DM.
Keywords: Type 2 diabetes mellitus, cardiovascular disease, blood pressure, antidiabetic medications, CV, CVD.
Graphical Abstract
Current Vascular Pharmacology
Title:Antidiabetic Drugs as Antihypertensives: New Data on the Horizon
Volume: 16 Issue: 1
Author(s): Vassiliki Mamakou, Ioanna Eleftheriadou, Niki Katsiki, Konstantinos Makrilakis, Konstantinos Tsioufis and Nikolaos Tentolouris*
Affiliation:
- First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens,Greece
Keywords: Type 2 diabetes mellitus, cardiovascular disease, blood pressure, antidiabetic medications, CV, CVD.
Abstract: Background: The prevalence of Type 2 Diabetes Mellitus (T2DM) is increasing worldwide; this is stimulating more research into the optimal management of this disease. Cardiovascular Disease (CVD) remains the commonest cause of death in individuals with T2DM. Besides hyperglycaemia, an explanation for the increased mortality in this population is the increased prevalence of comorbidities, such as hypertension and dyslipidaemia. Recent population-based studies described a prevalence of hypertension >80% in patients with T2DM. In the last decade new classes of antidiabetic medications have been developed that are effective not only for the management of hyperglycaemia and but also for tailoring treatment according to individual needs and characteristics. Regulatory authorities demand the new antidiabetic medications to be examined for Cardiovascular (CV) safety. Interestingly it has been shown, mainly through CV safety trials, that some new antidiabetic medications not only have glucose lowering effects, but also Blood Pressure (BP) lowering effects, contributing to CV risk reduction.
Conclusion: This review considers the effect of older and newer antidiabetic medications on BP in patients with T2DM.
Export Options
About this article
Cite this article as:
Mamakou Vassiliki , Eleftheriadou Ioanna , Katsiki Niki , Makrilakis Konstantinos , Tsioufis Konstantinos and Tentolouris Nikolaos*, Antidiabetic Drugs as Antihypertensives: New Data on the Horizon, Current Vascular Pharmacology 2018; 16 (1) . https://dx.doi.org/10.2174/1570161115666171010122332
DOI https://dx.doi.org/10.2174/1570161115666171010122332 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beneficial Effects of Traditional Chinese Medicine on the Treatment of Osteoporosis on Ovariectomised Rat Models
Current Drug Targets Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis
Reviews on Recent Clinical Trials Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Transient Focal Lesions in the Splenium of the Corpus Callosum with Restricted Diffusion: An Enigma
Current Medical Imaging Evaluation of Adverse Drug Event Information in US Manufacturer Labels
Current Drug Safety Chronopharmaceutical Delivery of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease
Reviews on Recent Clinical Trials P2Y12 Inhibitors: Pharmacologic Mechanism and Clinical Relevance
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point
Current Drug Targets Aqueous Humor Pharmacokinetics of Dorzolamide Loaded PLGAChitosan Nanoparticles by Ultra Performance Liquid Chromatography
Current Pharmaceutical Analysis Is Alzheimers Disease a Myth? When is Disease a Disease?
Current Alzheimer Research Meet Our Editor
Current Respiratory Medicine Reviews Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design From Gene to Epigene-Based Therapies Targeting the Vascular Endothelium
Current Vascular Pharmacology Hydrogen Sulfide: From Physiology to Pharmacology
Inflammation & Allergy - Drug Targets (Discontinued) Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design Recent Patents on Oral Combination Drug Delivery and Formulations
Recent Patents on Drug Delivery & Formulation EDITORIAL [Hot Topic: Novel Therapeutic Targets of the Renin-Angiotensin System (Guest Editor: Rajesh Kumar)]
Current Hypertension Reviews Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets